3,740 Shares of Merck & Co., Inc. $MRK Bought by Vista Capital Partners Inc.

Vista Capital Partners Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) during the third quarter, Holdings Channel.com reports. The fund purchased 3,740 shares of the company’s stock, valued at approximately $543,000.

Several other hedge funds have also recently modified their holdings of the stock. Cornerstone Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $8,798,000. Moors & Cabot Inc. boosted its stake in Merck & Co., Inc. by 1.9% in the 3rd quarter. Moors & Cabot Inc. now owns 96,460 shares of the company’s stock worth $14,017,000 after purchasing an additional 1,795 shares in the last quarter. Money Concepts Capital Corp boosted its stake in Merck & Co., Inc. by 0.9% in the 3rd quarter. Money Concepts Capital Corp now owns 32,863 shares of the company’s stock worth $4,775,000 after purchasing an additional 288 shares in the last quarter. Allworth Financial LP grew its position in Merck & Co., Inc. by 37.0% during the 3rd quarter. Allworth Financial LP now owns 285,781 shares of the company’s stock worth $41,527,000 after purchasing an additional 77,235 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Merck & Co., Inc. by 8.3% during the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after purchasing an additional 3,183,169 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of a number of recent analyst reports. Barclays upped their price target on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the company an “overweight” rating in a research note on Monday, October 26th. Royal Bank Of Canada lowered their price objective on shares of Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a research note on Friday, October 30th. Cantor Fitzgerald lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Sanford C. Bernstein boosted their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a report on Tuesday, August 4th. Finally, Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $155.74.

Get Our Latest Stock Report on MRK

Merck & Co., Inc. Trading Down 0.0%

Shares of NYSE:MRK opened at $147.74 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. Merck & Co., Inc. has a 52-week low of $91.49 and a 52-week high of $156.92. The stock has a market cap of $364.21 billion, a price-to-earnings ratio of 152.31, a PEG ratio of 6.77 and a beta of 0.13. The business has a 50-day moving average price of $146.16 and a 200-day moving average price of $128.61.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.

About Merck & Co., Inc.

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.